Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...
Bristol Myers Squibb has the first positive phase 3 results under its belt for mezigdomide, a second experimental drug in its much-trumpeted celmod development programme for multiple myeloma. Interim ...
BRISTOL, Tenn. — On Saturday, Bristol Motor Speedway will host “Racing Toward Change: Women Leading the Way,” a special Speedway Children’s Charities event presented by State Water Heaters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results